MedTrace Logo

Pelacarsen Roll-over Extension Program

NCT06875973 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 599

Last updated 2026-05-18

No results posted yet for this study

Summary

This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).

Conditions

Interventions

DRUG

Pelacarsen (TQJ230)

pelacarsen 80mg s.c. monthly

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-19
Primary Completion
2030-12-08
Completion
2030-12-08
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06875973 on ClinicalTrials.gov